BEIGF:OTCMKTS
BeOne Medicines
21,95Â US$
0,00%
(0,00) 1K
9-iyn, 12:49:46 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoBEIGF tikeri uchun statistika yaratilmoqda...
Bozor kapitali
42,40Â mlrd
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
24,92Â US$
52 haftalik eng past
21,95Â US$
Beta
0,84
Muomaladagi aksiyalar
1,43Â mlrd
Xodimlar soni
12Â ming
Bozor kapitali
42,40Â mlrd
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
24,92Â US$
52 haftalik eng past
21,95Â US$
Beta
0,84
Muomaladagi aksiyalar
1,43Â mlrd
Xodimlar soni
12Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
The Business Journals
·
23 daqiqa oldin
Axe Compute rings Nasdaq bell after pivoting from biotech to AI tokens
CNBC
·
58 daqiqa oldin
Citi's Scott Chronert on getting the S&P 500 to 8,100: We need both parts of the market performing
Altcoin Buzz
·
25 daqiqa oldin
Ripple-backed Evernorth debuts on Nasdaq with 473M XRP
Seeking Alpha
·
59 daqiqa oldin
Yes, The Technology Sector Will Lead S&P Profit Growth (Again)
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
BeOne Medicines haqida
CEOJohn Vincent Oyler | John Vincent Oyler
Xodimlar soni12Â ming
Asos solingan28-okt, 2010
Bosh ofislar-
Sektor-
Veb-saytbeonemedicines.com